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The original version of this article unfortunately contained
two mistakes. The presentation of Table 1 and Fig. 1 was
incorrect. The corrected versions are given below.
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Table 1 Eculizumab dosage
regimen, standard therapy
according to EMA/FDA
Weight category Induction phase Maintenance phase
Above 40 kg 900 mg, every week, for 4 weeks 1200 mg, in fifth week, every 14 days thereafter
30 to < 40 kg 600 mg, every week, for 2 weeks 900 mg, in third week, every 14 days thereafter
20 to < 30 kg 600 mg every week, for 2 weeks 600 mg, in third week, every 14 days thereafter
10 to < 20 kg 300 mg once 300 mg, in second week, every 14 days thereafter
5 to < 10 kg 300 mg once 300 mg, in second week, every 21 days thereafter
Eculizumab has to be administrated intravenously
EMA European Medicines Agency, FDA Food and Drug Administration
The online version of the original article can be found at https://doi.org/
10.1007/s00467-018-4091-3
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Paent with TMA
Eculizumab treatmentb
Standard protocol, dose therapy depending on body weight.
Evaluaon therapy aer 3 monthsc
In case the paent is in remission (normalized hematological parameters, normalized 
and/or stabilized kidney funcon and proteinuria, normal blood) adjustment of 
eculizumab therapy can be considered
In ancipaon of diagnoscs to rule out other causes of TMAa
&
Strong suspicion aHUS
Withdrawal or taperingd:
Scenario 1-5 figure 2
Monitoring aer therapy adjustment
Regular workup at every hospital visit is required or in case of disconnuaon aer 1,2,3,6,9 &12 
months aer withdrawal. Between hospital visits, dipsck analysis and/or blood pressure (aim for p50 
in children or below 130/80mmHg in adults) monitoring 3 mes per week at home is advised.
Fig. 1 Treatment algorithm. After adequate exclusion of other causes of
thrombotic microangiopathy (TMA) such as thrombocytopenic purpura
(TTP), Shiga toxin-producing Escherichia coli-hemolytic uremic syndrome
(STEC-HUS), or secondary TMA and in patients with strong suspicion of
atypical hemolytic uremic syndrome (aHUS), eculizumab treatment should
be started within 24 h after presentation. When the patient is stable and in
remission, withdrawal or tapering can be considered, depending on patient
characteristics (see Fig. 2). After therapy adjustment, strict monitoring is
essential. NB in case of antibodies against complement factor H, a different
treatment protocol has to be initiated as described by Loirat et al. [1]. a, For
extensive overview of practical diagnostics approach for TMA, see Fakhouri
etal.[3].b,Treatmentshouldpreferablybestartedwithin24hafterpresentation.
In adults with first episode of aHUS in native kidney, treatment with plasma
exchange (PE) for 4days (highvolumePEwith1.5plasmavolume) is advised
to allow diagnosis of secondary causes of aHUS. Adolescents may be
considered adults [33]. After exclusion of secondary causes of aHUS and if
the patient does not show a favorable response after 4 days of PE, treatment
should be switched to eculizumab. Starting treatment with eculizumab within
7 days after presentation in PE-resistant patients was effective in the clinical
trials [32]. In case the patient is PE sensitive, PE should be tapered and
discontinued in the course of 1month [9, 10]. c, Improvement of platelets and
lactate dehydrogenase (LDH) is expected within 2–4 weeks. If no response,
consider alternative diagnosis or inefficacy of eculizumab (C5 polymorphism
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